Organon Pharma (Ireland) Limited
2 Dublin Landings
N Wall Quay - North Dock
Dublin
D01 V4

Important information for healthcare professionals

Extending the use of **Implanon NXT** to allow insertion immediately postpartum (IPP) and immediately postabortion (IPA)
Implanon NXT, 68 mg, implant for subdermal use (etonogestrel)
PA 23198/017/001

30th April 2024

Dear Healthcare Professional,

Organon Pharma (Ireland) Limited would like to inform you of the following:
The therapeutic indication for Implanon NXT has been extended to allow insertion immediately postpartum (IPP) and immediately postabortion (IPA).

Based on a review of relevant data, previous restrictions on the timing of insertion of this long-acting reversible contraceptive (LARC) have been removed. Implanon NXT is now authorised for insertion:

- immediately postpartum in both breast-feeding and non breast-feeding women, based on individual benefit/risk assessment.
- immediately following abortion or miscarriage.

This change has resulted in updates to sections 4.2 (Posology and method of administration) and 4.6 (Fertility, pregnancy and lactation) of the Summary of Product Characteristics.

The authorised product information for Implanon NXT is available at www.hpra.ie and at www.medicines.ie.

Please ensure that all relevant staff are made aware of the content of this letter and that the information is communicated to all relevant parties.
The communication of this information has been agreed with the Health Products Regulatory Authority (HPRA).

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to HPRA Pharmacovigilance using the report form on the HPRA website, www.hpra.ie. Adverse events should also be reported to Organon at medinfo.roi@organon.com or contact 01- 5828250.

If you have any questions, please contact 01-5828260.

Yours faithfully,

Carola Rosseland, PhD
Medical Director, Central & Northern Europe

DN: IE-XPL-110050, DOP: April 2024

Organon Pharma (Ireland) Limited. Registered Office: 2 Dublin Landings, N Wall Quay - North Dock, Dublin, D01 V4A3
Registration No. 673650. Directors: Gerard Brennan, Neil Boyle, John Smith